Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus

Lookup NU author(s): Dr Rebecca HillORCiD, Professor Simon BaileyORCiD, Dr Debbie HicksORCiD, Professor Steven CliffordORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2026.Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to guide clinical care. The UK3CR Children’s Cancer Research Group (CRG) CNS Tumours Subgroup convened a multidisciplinary workshop to identify research priorities and establish a strategic framework for advancing clinical trials in this setting. Four high-priority tumour groups—craniopharyngioma, choroid plexus carcinoma (CPC), very high-risk medulloblastoma (VHR-MB), and rare embryonal and sarcomatous tumours (REST), including embryonal tumour with multilayered rosettes (ETMR)—were evaluated. Key outcomes included the feasibility of a UK-led craniopharyngioma trial, the need for enhanced national CPC data collection, and support for European early-phase platform trials in VHR-MB. REST highlighted transnational regulatory complexity requiring coordinated registries and parallel trial models. Cross-cutting barriers included regulatory discordance, contracting delays, fragmented funding, pharmacovigilance differences, data-sharing constraints, and interoperable infrastructures. The workshop emphasised innovative methodologies, including Bayesian/adaptive designs, platform trials, and external control arms, to maximise efficiency in small populations, alongside strengthened patient involvement and international collaboration. Collectively, these findings define a collaborative and internationally-aligned strategic roadmap to accelerate clinical research and improve outcomes in rare paediatric CNS tumours.


Publication metadata

Author(s): Adamski J, Apps JR, Depani S, Hill RM, Pizer B, Ajithkumar T, Bailey S, Bull KS, Carceller F, Cockle JV, Dineen RA, Douglas-Pugh JA, Gains J, Hicks D, Jorgensen M, Kilday J-P, Martinez-Barbera J-P, Ritzmann TA, Thompson E, Gates S, Hargrave D, Hackshaw A, Burke GAA, Clifford SC

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2026

Pages: Epub ahead of print

Online publication date: 22/08/2026

Acceptance date: 10/08/2026

Date deposited: 01/09/2026

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Springer Nature

URL: https://doi.org/10.1038/s41416-026-03589-6

DOI: 10.1038/s41416-026-03589-6

Data Access Statement: This manuscript does not contain any foundational data.


Altmetrics

Altmetrics provided by Altmetric


Share